ClinicalTrials.gg
Status unknownNCT04992962Updated Aug 6, 2021

Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

A Phase 2 interventional study of CBD/CBN and CBD/THC in Osteoarthritis, Knee, sponsored by Pure Green. Status unknown at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Pure Green · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
356th of 691
66 · median 72
Started
2021
with 59 others
Phase 2
111 of 796
13 open now
Registered
598th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 356th largest by planned enrollment of the 691 interventional ones that give a count, is one of 60 that started in 2021, is one of 111 in phase 2, and was the 598th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of PG-OA-10CN and PG-OA-5TH tablets as a better pain reliever in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo.

Read the detailed description

Subjects will be enrolled in the study for a maximum of 36 days, including a 7-day screening period, 28 days of active product administration, and followed by a post-treatment follow-up within 1 day.

The primary objective of this study is:

  • To evaluate the efficacy of PG-OA-10CN and PG-OA-5TH for the treatment of pain associated with osteoarthritis of the knee, compared to a placebo control.

The secondary objectives of this study are:

  • To evaluate differences of efficacy between PG-OA-10CN and PG-OA-5TH
  • To evaluate the impact of PG-OA-10CN and PG-OA-5TH for stiffness, function in daily living, function in sport and recreation, and knee related quality of life as assessed by the KOOS.
  • To evaluate the safety of PG-OA-10CN and PG-OA-5TH for the treatment of pain associated with osteoarthritis of the knee.
03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • CBD
  • Cannabidiol
  • CBN
  • Cannabinol
  • THC
  • Osteoarthritis
  • Pain
  • Placebo
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is at least 21 years of age;
  2. Subject has a diagnosis of osteoarthritis of the knee as determined by the subject's primary care physician or related health care provider.
  3. Subject reports an average NPRS score of ≥ 5 in the 7 days prior to enrollment.
  4. If female, the subject is (> 1 year), surgically sterile (> 3 months), had a hysterectomy, or is currently using 2 effective forms of .
  5. Subject has not taken marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and agrees to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study.
  6. If subject is currently taking a prohibited medication, subject must be willing to and complete a of these medications during the screening period and prior to starting study treatment.
  7. Subject has not taken any NSAIDs and/or acetaminophen for at least 2 days prior to starting study treatment.
  8. Subject is willing to provide his/her written to participate in the study as stated in the informed consent document.
  9. Subject is willing to use an electronic diary to enter trial information for 29 days.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or lactating;
  2. Subject has an allergy to cannabis, the Cannabaceae plant family (e.g., hemp, hops), palmitoylethanolamide, or terpenes;
  3. Subject has a known allergy to active or inert ingredients of the product;
  4. Subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: Cannabis or any cannabinoid products; Any drug or herbal product that influences the endocannabinoid system (ECS));
  5. Subject is taking marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and does not promise that they will not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study;
  6. Subject is currently being treated with antibiotics for sinus, throat, or lung infections;
  7. Subject has shortness of breath associated with allergies;
  8. Subject has uncontrolled asthma;
  9. Subject has a fever and/or productive cough;
  10. Subject has unstable angina, uncontrolled hypertension;
  11. Subject currently or has a history of congestive heart failure;
  12. Subject has any other unstable medical condition;
  13. Subject has a personal or family history of schizophrenia;
  14. Subject has a personal history or currently has suicidal ideation or attempted suicide;
  15. Subject has a major neurological disorder, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury/head injury, and seizures.
  16. Subject has taken pharmaceutical pain medicine, including OTC pain medicine of any kind, or has taken a NSAID and/or acetaminophen within 2 days of starting study treatment.
  17. Subject has taken a prohibited medication during the screening period and prior to starting study treatment or is unwilling to stop these medications.
  18. Subject has an allergy to, or has an intolerance to, NSAIDs or acetaminophen.
  19. Subject has taken any form of , including a local steroid injection in the knee, within 1 month of starting study treatment.
  20. Subject has received any invasive interventions or surgery of the knee.
  21. Subject has a history of substance or alcohol abuse.
  22. Subject has illness, including cardiovascular disorders.
  23. Subject has any condition in which the investigator believes will confound the data of the study or could put the subject at risk of harm.
  24. Subject does not have access to a smart phone or does not know how to use a smart phone application.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    CBD/CBN

    Participants will receive a 28-day supply of CBD/CBN sublingual tablets to be taken 3 times a day for 28 days.

    Drug: CBD/CBN

  • Experimental
    CBD/THC

    Participants will receive a 28-day supply of CBD/THC sublingual tablets to be taken 3 times a day for 28 days.

    Drug: CBD/THC

  • Placebo comparator
    Placebo

    A placebo sublingual tablet to be taken three times a day for 28 days

    Drug: Placebo

Interventions

  • DrugCBD/CBN

    Drug pages: Cannabidiol · Cannabinol

    A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.

  • DrugCBD/THC

    Drug page: Nabiximols

    A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.

  • DrugPlacebo

    An inactive compound.

06

What researchers measure

Primary outcomes

  1. Pain as assessed by Numerical Pain Rating Scale (NPRS)

    To evaluate the impact of PG-OA-10CN and PG-OA-10TC on the subject's osteoarthritis of the knee pain as assessed by utilizing a Numeric Pain Rating Scale (NPRS). NPRS is from 0-10, where higher scores indicate worse pain and lower scores indicate less pain reported by the subject.

    Time frame: 28 Days

  2. Pain as assessed by the Knee Injury and Osteoarthritis Outcome Score (KOOS)

    To evaluate the impact of PG-OA-10CN and PG-OA-10TC on the subject's osteoarthritis of the knee pain as assessed by the Knee Injury and Osteoarthritis Outcome Score (KOOS). KOOS is scored from 0-100, where 0 represents extreme problems and 100 represents no problems, as reported by the subject.

    Time frame: 28 Days

Secondary outcomes

  1. Incidence of treatment-related adverse events as assessed by CTCAE v4.0.

    To evaluate the safety of PG-OA-10CN and PG-OA-10TC for the treatment of pain associated with osteoarthritis of the knee compared to a placebo control assessed by Common Terminology Criteria For Adverse Events (CTCAE) v4.0.

    Time frame: 28 Days

07

Study locations

1 of 1 sites recruiting
  • Pure Green Pharmaceuticals
    West Bloomfield, Michigan 48323, United States
    Recruiting
08

References and documents

Publications

  • Papaleontiou M, Henderson CR Jr, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, Reid MC. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2010 Jul;58(7):1353-69. doi: 10.1111/j.1532-5415.2010.02920.x. Epub 2010 Jun 1. PubMed 20533971 ↗
  • Eli Lilly & Company. (2019). Cymbalta: Highlights of prescribing information. Indianapolis, IN.
  • Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010 Aug;26(3):355-69. doi: 10.1016/j.cger.2010.03.001. Erratum In: Clin Geriatr Med. 2013 May;29(2):ix. PubMed 20699159 ↗
  • Ahrnsbrak, R., Bose, J., Hedden, S. L., Lipari, R. N., & Park-Lee, E. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 1572.
  • Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452. doi: 10.15585/mmwr.mm655051e1. PubMed 28033313 ↗
  • Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011 Dec;27(12):2361-72. doi: 10.1185/03007995.2011.633502. Epub 2011 Nov 9. Erratum In: Curr Med Res Opin. 2012 May;28(5):822. PubMed 22017192 ↗
  • Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50-2. doi: 10.1093/rheumatology/kei183. Epub 2005 Nov 9. PubMed 16282192 ↗
  • Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008 Jun 17;178(13):1669-78. doi: 10.1503/cmaj.071178. PubMed 18559804 ↗
  • Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9. PubMed 11690728 ↗
  • Michener LA, Snyder AR, Leggin BG. Responsiveness of the numeric pain rating scale in patients with shoulder pain and the effect of surgical status. J Sport Rehabil. 2011 Feb;20(1):115-28. doi: 10.1123/jsr.20.1.115. PubMed 21411827 ↗
  • Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine (Phila Pa 1976). 2005 Jun 1;30(11):1331-4. doi: 10.1097/01.brs.0000164099.92112.29. PubMed 15928561 ↗
  • Ogura T, Ackermann J, Mestriner AB, Merkely G, Gomoll AH. The Minimal Clinically Important Difference and Substantial Clinical Benefit in the Patient-Reported Outcome Measures of Patients Undergoing Osteochondral Allograft Transplantation in the Knee. Cartilage. 2021 Jan;12(1):42-50. doi: 10.1177/1947603518812552. Epub 2018 Nov 22. PubMed 30463426 ↗
  • Jacquet C, Pioger C, Khakha R, Steltzlen C, Kley K, Pujol N, Ollivier M. Evaluation of the "Minimal Clinically Important Difference" (MCID) of the KOOS, KSS and SF-12 scores after open-wedge high tibial osteotomy. Knee Surg Sports Traumatol Arthrosc. 2021 Mar;29(3):820-826. doi: 10.1007/s00167-020-06026-0. Epub 2020 Apr 27. PubMed 32342141 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Oct 2021, 3 months after the start.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 3 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 6, 2021
StartActual
Jul 29, 2021
Primary completionEst.
Oct 30, 2021
CompletionEst.
Nov 14, 2021
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04992962
Lead sponsor
Pure Green
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Jul 29, 2021
Primary completion
Oct 30, 2021 (estimated)
Completion
Nov 14, 2021 (estimated)
Last update
Aug 6, 2021

Study contacts

Matthew Caloura
Contact
mcaloura@pgpharma.co
(248) 802-4380
Debra Kimless, M.D.
Contact
dkimlessmd@pgpharma.co
(248) 920-8761
Debra Kimless, M.D.
principal investigator · Pure Green Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabidiol · Cannabinol · Nabiximols

Start the discussion